Home » ARRAY BIOPHARMA BEGINS TRIAL OF MEK INHIBITOR
ARRAY BIOPHARMA BEGINS TRIAL OF MEK INHIBITOR
Array BioPharma has announced the initiation of a Phase I clinical trial for its proprietary small molecule, ARRY-438162, a novel MEK inhibitor for the treatment of inflammatory disease.
ARRY-438162 will be evaluated in dose escalation studies in normal, healthy volunteers. Array scientists demonstrated ARRY-438162 to be potent, selective, well-tolerated and efficacious in preclinical models of human inflammatory diseases.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May